 | Up a level |
Codilupi, Tamara; Szybinski, Jakub; Arunasalam, Stefanie; Jungius, Sarah; Dunbar, Andrew C; Stivala, Simona; Brkic, Sime; Albrecht, Camille; Vokalova, Lenka; Yang, Julie L; Buczak, Katarzyna; Ghosh, Nilabh; Passweg, Jakob R; Rovo, Alicia; Angelillo-Scherrer, Anne; Pankov, Dmitry; Dirnhofer, Stephan; Levine, Ross L; Koche, Richard and Meyer, Sara C (2024). Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable. Clinical cancer research, 30(3), pp. 586-599. American Association for Cancer Research 10.1158/1078-0432.CCR-23-0163
Dunbar, Andrew J; Bowman, Robert L; Park, Young C; O'Connor, Kavi; Izzo, Franco; Myers, Robert M; Karzai, Abdul; Zaroogian, Zach; Kim, Won Jun; Fernandez-Maestre, Ines; Waarts, Michael R; Nazir, Abbas; Xiao, Wenbin; Codilupi, Tamara; Brodsky, Max; Farina, Mirko; Cai, Louise; Cai, Sheng F; Wang, Benjamin; An, Wenbin; ... (2024). Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms. (In Press). Cancer discovery American Association for Cancer Research 10.1158/2159-8290.CD-22-0952
Brkic, Sime; Stivala, Simona; Santopolo, Alice; Szybinski, Jakub; Jungius, Sarah; Passweg, Jakob R; Tsakiris, Dimitrios; Dirnhofer, Stefan; Hutter, Gregor; Leonards, Katharina; Lischer, Heidi E L; Dettmer, Matthias S; Neel, Benjamin G; Levine, Ross L; Meyer, Sara C (2021). Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia, 35(10), pp. 2875-2884. Springer Nature 10.1038/s41375-021-01391-2
Stivala, Simona; Codilupi, Tamara; Brkic, Sime; Baerenwaldt, Anne; Ghosh, Nilabh; Hao-Shen, Hui; Dirnhofer, Stephan; Dettmer, Matthias S.; Simillion, Cedric; Kaufmann, Beat A; Chiu, Sophia; Keller, Matthew; Kleppe, Maria; Hilpert, Morgane; Buser, Andreas S; Passweg, Jakob R; Radimerski, Thomas; Skoda, Radek C; Levine, Ross L and Meyer, Sara C (2019). Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. The journal of clinical investigation, 129(4), pp. 1596-1611. American Society for Clinical Investigation 10.1172/JCI98785
Kunimoto, Hiroyoshi; Meydan, Cem; Nazir, Abbas; Whitfield, Justin; Shank, Kaitlyn; Rapaport, Franck; Maher, Rebecca; Pronier, Elodie; Meyer, Sara C.; Garrett-Bakelman, Francine E; Tallman, Martin; Melnick, Ari; Levine, Ross L; Shih, Alan H (2018). Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer cell, 33(1), 44-59.e8. Cell Press 10.1016/j.ccell.2017.11.012
Nitulescu, Ioana I; Meyer, Sara C.; Wen, Qiang Jeremy; Crispino, John D; Lemieux, Madeleine E; Levine, Ross L; Pelish, Henry E; Shair, Matthew D (2017). Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. EBioMedicine, 26, pp. 112-125. Elsevier 10.1016/j.ebiom.2017.11.013
Meyer, Sara C; Keller, Matthew D; Chiu, Sophia; Koppikar, Priya; Guryanova, Olga A; Rapaport, Franck; Xu, Ke; Manova, Katia; Pankov, Dmitry; O'Reilly, Richard J; Kleppe, Maria; McKenney, Anna Sophia; Shih, Alan H; Shank, Kaitlyn; Ahn, Jihae; Papalexi, Eftymia; Spitzer, Barbara; Socci, Nick; Viale, Agnes; Mandon, Emeline; ... (2015). CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer cell, 28(1), pp. 15-28. Cell Press 10.1016/j.ccell.2015.06.006
Meyer, Sara C; Keller, Matthew D; Woods, Brittany A; LaFave, Lindsay M; Bastian, Lennart; Kleppe, Maria; Bhagwat, Neha; Marubayashi, Sachie; Levine, Ross L (2014). Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood, 124(14), pp. 2280-2284. American Society of Hematology 10.1182/blood-2014-03-560441
Meyer, Sara C; Levine, Ross L (2014). Translational implications of somatic genomics in acute myeloid leukaemia. The lancet oncology, 15(9), e382-e394. Elsevier 10.1016/S1470-2045(14)70008-7
Meyer, Sara C; Levine, Ross L (2014). Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clinical cancer research, 20(8), pp. 2051-2059. American Association for Cancer Research 10.1158/1078-0432.CCR-13-0279
